Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H10F6N6O |
Molecular Weight | 428.2913 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C(=C\N1C=NC(=N1)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)\C3=CN=CN=C3
InChI
InChIKey=JFBAVWVBLRIWHM-AWNIVKPZSA-N
InChI=1S/C17H10F6N6O/c18-16(19,20)11-1-9(2-12(3-11)17(21,22)23)15-27-8-29(28-15)6-13(14(24)30)10-4-25-7-26-5-10/h1-8H,(H2,24,30)/b13-6+
Molecular Formula | C17H10F6N6O |
Molecular Weight | 428.2913 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Eltanexor (KPT-8602) is an investigational second-generation Selective Inhibitor of Nuclear Export (SINE) compound that is designed to selectively block the nuclear export protein XPO1. Most of the key tumor suppressor proteins (TSPs), are cargos of XPO1 and inhibition of XPO1 by eltanexor is believed to sequester TSPs in the nucleus where they can carry out their normal functions. Karyopharm Therapeutics is developing eltanexor for the treatment of relapsed/refractory cancers.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27211268 | https://www.karyopharm.com/pipeline/oral-eltanexor/
Curator's Comment: Eltanexor has minimal penetration of the blood-brain barrier.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. | 2017 Jan |
|
Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. | 2018 Oct 19 |
|
Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. | 2019 Apr 1 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.bloodjournal.org/content/130/suppl_1/3134
In Phase 1/2 study in patients with refractory multiple myeloma, using a 3+3 dose escalation design, eltanexor is dosed orally (QDx5 or QoDx3 weekly) for a 28-day cycle with a starting dose of 5 mg.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 19:28:08 GMT 2023
by
admin
on
Sat Dec 16 19:28:08 GMT 2023
|
Record UNII |
Q59IQJ9NTK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
857421
Created by
admin on Sat Dec 16 19:28:08 GMT 2023 , Edited by admin on Sat Dec 16 19:28:08 GMT 2023
|
||
|
NCI_THESAURUS |
C129824
Created by
admin on Sat Dec 16 19:28:08 GMT 2023 , Edited by admin on Sat Dec 16 19:28:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C125193
Created by
admin on Sat Dec 16 19:28:08 GMT 2023 , Edited by admin on Sat Dec 16 19:28:08 GMT 2023
|
PRIMARY | |||
|
1642300-52-4
Created by
admin on Sat Dec 16 19:28:08 GMT 2023 , Edited by admin on Sat Dec 16 19:28:08 GMT 2023
|
PRIMARY | |||
|
FG-144
Created by
admin on Sat Dec 16 19:28:08 GMT 2023 , Edited by admin on Sat Dec 16 19:28:08 GMT 2023
|
PRIMARY | |||
|
10496
Created by
admin on Sat Dec 16 19:28:08 GMT 2023 , Edited by admin on Sat Dec 16 19:28:08 GMT 2023
|
PRIMARY | |||
|
86345880
Created by
admin on Sat Dec 16 19:28:08 GMT 2023 , Edited by admin on Sat Dec 16 19:28:08 GMT 2023
|
PRIMARY | |||
|
100000183571
Created by
admin on Sat Dec 16 19:28:08 GMT 2023 , Edited by admin on Sat Dec 16 19:28:08 GMT 2023
|
PRIMARY | |||
|
Q59IQJ9NTK
Created by
admin on Sat Dec 16 19:28:08 GMT 2023 , Edited by admin on Sat Dec 16 19:28:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|